Engineered Adenovirus vectors for transient and quantitative gene expression or knockdown
SIRION BIOTECH`s patented BAC technology enables adenovirus construction in less than 5 weeks. The system complies with all standard safety criteria by using replication deficient E1/E3 deleted serotype Ad5 as basis. Virtually every desired gene or shRNA expression construct is possible, with a capacity of 7.5 kb.
- Strong cell accessibility dividing and non-dividing cell
- Tight control of gene expression levels
- High titer productions for transgene delivery in vivo
- Inducible expression available to study toxic gene modulations
- No site specific mutagenesis due to episomal genome expression
In addition to standard Adeno applications, SIRION offers a range of further customization options including a choice of custom promoters and transduction enhancers for hard-to-transduce cell types. Any project is thoroughly discussed with our customers to ensure that the resulting particles are feasibly designed and fit the final application.
Adenovirus based virus-like-vaccines targeting endogenous retroviruses can eliminate growing colorectal cancers in mice. Neukirch L, Nielsen TK, Laursen H, Daradoumis J, Thirion C, Holst PJ.Oncotarget. 2019 Feb 15;10(14):1458-1472. doi: 10.18632/oncotarget.26680. eCollection 2019 Feb 15.
Replication deficient human adenovirus vector serotype 19a/64: Immunogenicity in mice and female cynomolgus macaques. Ragonnaud E, Schroedel S, Mariya S, Iskandriati D, Pamungkas J, Fougeroux C, Daradoumis J, Thomsen AR, Neukirch L, Ruzsics Z, Salomon M, Thirion C, Holst PJ. Vaccine. 2018 Oct 1;36(41):6212-6222. doi: 10.1016/j.vaccine.2018.07.075. Epub 2018 Sep 3.
Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses. Lapuente D, Ruzsics Z, Thirion C, Tenbusch M.Vaccine. 2018 May 3;36(19):2712-2720. doi: 10.1016/j.vaccine.2018.02.075. Epub 2018 Apr 5.
Vaccine vectors based on Adenovirus 19a/64 exhibit broad cellular tropism and potently restimulate HCMV-specific T cell responses ex vivo. Kiener R, Fleischmann M, Schwegler C, Ruzsics Z, Thirion C, Schrödel S, Asbach B, Wagner R. Sci Rep. 2018 Jan 24;8(1):1474. doi: 10.1038/s41598-018-19874-1.
Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Thirion C, Lochmüller H, Ruzsics Z, Boelhauve M, König C, Thedieck C, Kutik S, Geiger C, Kochanek S, Volpers C, Burgert HG. Hum Gene Ther. 2006 Feb;17(2):193-205.